Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis

Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best strategy to delay irreversible neurological damage and progression of multiple sclerosis (MS). In European healthcare systems, however, patient access to HE DMTs in MS is often restricted to later stages of the...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neurology Vol. 269; no. 3; pp. 1670 - 1677
Main Authors:	Filippi, Massimo, Danesi, Romano, Derfuss, Tobias, Duddy, Martin, Gallo, Paolo, Gold, Ralf, Havrdová, Eva Kubala, Kornek, Barbara, Saccà, Francesco, Tintoré, Mar, Weber, Jörg, Trojano, Maria
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2022 Springer Nature B.V
Subjects:	Consensus Health care Humans Medicine Medicine & Public Health Multiple sclerosis Multiple Sclerosis - drug therapy Neurology Neuroradiology Neurosciences Patients Resource allocation Short Short Commentary Healthcare system High-efficacy disease-modifying therapy Pharmacoeconomics Multiple sclerosis Benefit–risk profile Unrestricted access
ISSN:	0340-5354, 1432-1459, 1432-1459
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!